CAR-T cell treatment is effective against hematologic malignancies but encounters limitations in treating solid tumors due to the expression of checkpoint PD-1/PD-L1 within the tumor microenvironment (TME), which directly limits T-cell responses (75, 76). The gene discussed is PDCD1; the disease is neoplasm.